| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE39264 | BAUSCH | Pharmaceutical combination |
Aug, 2016
(7 years ago) | |
| US6514980 | BAUSCH | Nucleoside analogs in combination therapy of herpes simplex infections |
Jul, 2018
(5 years ago) | |
| US7223387 | BAUSCH | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
Nov, 2022
(1 year, 5 months ago) | |
Xerese is owned by Bausch.
Xerese contains Acyclovir; Hydrocortisone.
Xerese has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Xerese are:
- USRE39264
- US6514980
- US7223387
Xerese was authorised for market use on 31 July, 2009.
Xerese is available in cream;topical dosage forms.
Xerese can be used as combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older), new combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older).
The generics of Xerese are possible to be released after 13 November, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 31, 2012 |
| New Patient Population(NPP) | Jan 22, 2017 |
Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient
Market Authorisation Date: 31 July, 2009
Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolesc...
Dosage: CREAM;TOPICAL
XERESE family patents
